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Abstract
Human neutrophils (PMN) are potentially a major source of platelet-activating factor (PAF) produced during inflammatory responses. The
stimulated synthesis of PAF in PMN is carried out by a phospholipid remodeling pathway involving three enzymes: acetyl-CoA:lyso-PAF
acetyltransferase (acetyltransferase), type IV phospholipase A2 (cPLA2) and CoA-independent transacylase (CoA-IT). However, the
coordinated actions and the regulatory mechanisms of these enzymes in PAF synthesis are poorly defined. A23187 has been widely used to
activate the remodeling pathway, but it has not been shown how closely its actions mimic those of physiological stimuli. Here we address this
important problem and compare responses of the three remodeling enzymes and PAF synthesis by intact cells. In both A23187- and N-
formyl-methionyl-leucyl-phenylalanine (fMLP)-stimulated PMN, acetyltransferase activation is blocked by SB 203580, a p38 MAP kinase
inhibitor, but not by PD 98059, which blocks activation of the ERKs. In contrast, either agent attenuated cPLA2 activation. Correlating with
these results, SB 203580 decreased stimulated PAF formation by 60%, whereas PD 98059 had little effect. However, the combination of both
inhibitors decreased PAF formation to control levels. Although a role for CoA-IT in PAF synthesis is recognized, we did not detect activation
of the enzyme in stimulated PMN. CoA-IT thus appears to exhibit full activity in resting as well as stimulated cells. We conclude that the
calcium ionophore A23187 and the receptor agonist fMLP both act through common pathways to stimulate PAF synthesis, with p38 MAP
kinase regulating acetyltransferase and supplementing ERK activation of cPLA2.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-
3-phosphocholine; 1-O-alkyl-2-acetyl-GPC; PAF) is a po-
tent, bioactive phospholipid that mediates diverse phys-
iological and pathological responses. Polymorphonuclear
leukocytes (PMN), a particularly well-studied cell type
and a potential major source of PAF in vivo, produce this
mediator via a phospholipid-remodeling pathway. Stimu-
lated PAF synthesis is initiated by the formation of 1-O-
alkyl-2-lyso-GPC (lyso-PAF) by either phospholipase A2
(PLA2) hydrolysis of 1-O-alkyl-2-arachidonoyl-GPC or by
the CoA-independent transacylase (CoA-IT), which trans-
fers the sn-2 acyl chain from 1-O-alkyl-2-acyl-GPC to an
acceptor lyso-phospholipid. The lyso-PAF that is formed by
either of these routes is then acetylated by acetyl-CoA: 1-O-
alkyl-2-lyso-GPC acetyltransferase (acetyltransferase) to
form PAF (for review, see Ref. [1]). Although the enzymes
believed to be responsible for the remodeling pathway have
been identified, their coordinated actions, regulatory
roles(s), and the upstream signals that are critical to the
conduct of this pathway have not been established. Con-
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sequently, despite many studies of PAF metabolism, the
regulation of PAF synthesis is not well understood.
Two mitogen-activated protein kinase (MAP kinase)
cascades, the extracellular signal-regulated kinases (ERKs)
and p38 MAP kinases, have emerged as important elements
in the regulation of PMN function [2–4]. These two kinase
cascades appear to have overlapping but distinct functions
with regard to both upstream activators and downstream
targets. Both pathways are activated to a similar extent by
chemotactic factors such as N-formyl-methionyl-leucyl-
phenylalanine (fMLP) [5], whereas p38 MAP kinase is
preferentially or selectively activated by inflammatory
cytokines and lipopolysaccharide (LPS) [6,7]. In down-
stream signaling, the ERK and p38 MAP kinase pathways
can both activate the 85 kDa cytosolic PLA2 (cPLA2) [8,9],
a PLA2 believed to be essential for PAF synthesis [10],
whereas only p38 MAP kinase appears to activate the
acetyltransferase [11].
In spite of these advances in our understanding of the
relationships between the MAP kinases and the individual
enzymes of the remodeling pathway, the roles of p38 MAP
kinase and ERKs in stimulus-induced PAF synthesis
remain largely unexplored. In studies reported here, we
examined the role of p38 MAP kinase and the ERKs in
regulating all three individual enzymes of the remodeling
pathway and assessed their respective roles in PAF syn-
thesis in intact PMN. We focused on the actions of two
agonists: the chemotactic oligopeptide fMLP and the
calcium ionophore A23187, both of which are known to
stimulate PAF synthesis and AA release. Because A23187
induces robust AA release and PAF formation, it has long
been used as a model stimulus to study PAF metabolism. It
is therefore important to determine whether these two
different stimulus types, physiological and nonphysiolog-
ical, elicit comparable responses in the remodeling path-
way. Some of these results have been previously reported
in abstract form [12].
2. Experimental procedures
2.1. Materials
1-O-[1,2-3H]Hexadecyl-2-lyso-sn-glycero-3-phospho-
choline ([3H]lyso-PAF; 56 Ci/mmol) was synthesized as
described by Wyrick et al. [13]. The stock [3H]lyso-PAF
was mixed with unlabeled lyso-PAF in chloroform and
methanol (4:1, v/v) when preparations of lower radiospe-
cific activity were desired. 1-Stearoyl-2-[1-14C]arachido-
noyl-sn-glycero-3-phosphocholine (55 mCi/mmol) was
obtained from Amersham (Arlington Heights, IL). Na[3H]a-
cetate was obtained from American Radiolabeled Chemicals
(St Louis, MO); phospholipid standards, including unla-
beled lyso-PAF, phosphatidylcholine (PC), and PAF were
from Avanti Polar Lipids (Birmingham, AL). MAP kinase
kinase (MEK) inhibitor, PD 98059; p38 MAP kinase
inhibitor, SB 203580; and calcium ionophore, A23187
(Streptomyces chartreusensis; free acid), were purchased
from Calbiochem-Novabiochem Intl. (La Jolla, CA). Iso-
lymph was from Gallard-Schlesinger (Carle Place, NY) and
Dextran T-500 was from Pharmacia LKB Biotechnology
(Uppsala, Sweden). Silica gel G plates were purchased from
Analtech (Newark, DE). Leupeptin, pepstatin, fMLP and
Dulbecco’s phosphate buffered saline (PBS) were from
Sigma (St Louis, MO).
Phosphospecific antibodies against ERK (residues 196–
209 of tyrosine phosphorylated human ERK-1) and against
p38 MAP kinase (residues 171–186 of tyrosine phosphory-
lated human p38 MAP kinase) were from New England
Bio-Labs (Beverly, MA). Rabbit polyclonal antibody
against cPLA2 was purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). Horseradish peroxidase-conjugated
goat anti-rabbit antibody was purchased from Transduction
Laboratories (Lexington, KY). Enhanced chemilumines-
cence detection reagents and polyvinylidene difluoride
membranes (PVDF) were from DuPont NEN Research
Products (Boston, MA).
2.2. Preparation of neutrophils
Neutrophils were prepared as previously described [14],
with some modification. Briefly, heparinized blood contain-
ing 4 mM EDTA was sedimented using dextran to remove
red blood cells. The blood cells were further separated by
centrifugation over Isolymph, and contaminating red blood
cells were removed by brief hypotonic lysis. Cell popula-
tions consisted of >95% PMN. Isolated neutrophils were
suspended at 3.5 107 cells/1 ml in PBS containing 1.4 mM
CaCl2; however, for cPLA2 activation experiments, cells
were resuspended at 3.0 107 cells/3 ml.
2.3. SDS-PAGE and immunoblotting
For phosphospecific ERK and p38 MAP kinase immu-
noblotting, whole cell sonicates (2.5 105 cell equivalents)
were resolved by SDS-PAGE (12% polyacrylamide), elec-
trophoretically transferred to PVDF membranes overnight
and immunoblotted. Detection of the phosphorylated forms
of ERK and p38 MAP kinase was carried out according to
the protocol provided by New England Bio-Labs.
cPLA2 gel shift analysis was performed on PMN
sonicate (100 Ag protein) in which the nuclei and the
granules, which are rich in proteases, were removed by
centrifugation (16,000 g, 4 jC, 30 min). The sonicate
was resolved by SDS-PAGE (7.5% polyacrylamide),
transferred to PVDF membranes overnight and immuno-
blotted.
2.4. Acetyltransferase activity assay
Acetyltransferase activity was assayed as described
[11,15] with some modifications. Briefly, PMN (3.5 107/
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1 ml) in PBS containing 1.4 mM Ca2 + were incubated for 30
min at 37 jC in the presence or absence of 50 AM PD 98059
and/or 20 AM SB 203580; DMSO was used as a vehicle
control. Cells were treated with or without 10 AM A23187
for 10 min. The reaction was stopped by addition of 35 ml
chilled (4 jC) PBS. All subsequent manipulations were
carried out at 4 jC. Cells were centrifuged for 10 min at
400 g and the pellet resuspended in 1 ml of protection
buffer (0.2 M Tris–HCl, pH 7.4, containing 50 Ag/ml each of
pepstatin A and leupeptin, 10 mM NaF, and 0.2 mM
Na3VO4). Cells were sonicated twice for 8 s at a power
setting of 2 with a probe sonicator (Heat System, Inc). The
sonicate was centrifuged at 16,000 g for 20 min to remove
nuclei, granules and cellular debris, and the supernatant was
centrifuged at 100,000 g for 60 min to obtain a microsomal
membrane pellet. The pellet was resuspended in 1 ml 0.2 M
Tris–HCl (pH 7.4), and the protein concentration of the
suspension was determined by the method of Bradford [16]
using bovine serum albumin (BSA) as standard.
The acetyltransferase reaction was initiated by adding
aliquots of the microsomal preparation (10 Ag protein) to
prewarmed tubes containing 100 AM acetyl-CoA and
[3H]lyso-PAF (16 AM, 0.1 ACi/tube; 1 ml final volume).
After 15-min incubation at 37 jC, the reactions were
stopped by extracting the lipids [17]. [3H]PAF was meas-
ured after separation by TLC as described below.
2.5. CoA-IT activity assay
PMN (3.5 107/1 ml) in PBS containing 1.4 mM Ca2 +
were stimulated with tumor necrosis factor alpha (TNFa,
3.16 nM, 10 min), A23187 (10 AM, 10 min), fMLP (10 AM,
10 min) or phorbol-12-myristate-13-acetate (PMA, 100 nM,
5 min). In some experiments, PMN were pretreated with or
without the MAP kinase inhibitors, as described above, prior
to stimulation. Microsomal fractions were isolated as
described above, and protein concentration determined by
the method of Bradford [16]. CoA-IT activity was measured
using the acceptor assay described by Venable et al. [18],
with somemodification. Briefly, each reaction tube contained
900 Al 0.2 M Tris–HCl (pH 7.4) to which was added
[3H]lyso-PAF (0.2 ACi, 5 AM) dissolved in 50 Al of Tris
buffer (pH 7.4) containing 2 mg BSA/ml. Tubes were
prewarmed for 10 min (37 jC), and reactions were initiated
by adding 5–10 Agmicrosomal membrane protein (1 ml final
volume). Samples were shaken for 15 min (37 jC), and the
reactions stopped by extracting the lipids [17]. 1-O-[3H]hex-
adecyl-2-acyl-GPC was separated by TLC as described
below and measured by liquid scintillation counting. Typi-
cally, 10–20% of added [3H]lyso-PAF was acylated.
In some experiments, a donor assay was used to measure
CoA-IT activity [18]. PMN were labeled with [3H]lyso-PAF
(60,000 dpm/3.5 107 cell/ml) in PBS without Ca2 + for 60
min at 37 jC. PMNwere washed three times with PBS (4 jC)
containing 2 mg/ml BSA and rinsed an additional time with
PBS alone. Cells were resuspended (3.5 107/ml) in PBS
containing 1.4 mM CaCl2, allowed to rest for 20 min (4 jC),
then warmed for 20 min (37 jC). Under these conditions,
PMN convert >90% of incorporated [3H]lyso-PAF to 1-O-
[3H]alkyl-2-arachidonoyl-GPC [19]. Cells were stimulated
and microsomal membranes were prepared as described
above. The same buffers and conditions were used as in
the acceptor assay. The reaction was initiated by adding 30
AMunlabeled 1-O-alk-1V-enyl-2-lyso-GPE. The reaction was
stopped by extraction, and the transacylase product, 1-O-
[3H]hexadecyl-2-lyso-GPC, was isolated by TLC and quan-
titated by liquid scintillation counting. Typically, 10–20% of
the labeled PC was converted to 1-O-[3H]hexadecyl-2-lyso-
GPC.
2.6. cPLA2 activity assay
PMN (3.0 107/3 ml) in PBS containing 1.4 mM Ca2 +
were incubated for 30 min (37 jC) with or without 50 AM
PD 98059 and/or 20 AM SB 203580; DMSO was used as
an inhibitor vehicle control. Cells were then sequentially
treated with or without 10 AM A23187 for 2 min, diluted
with 35 ml chilled (4 jC) PBS, centrifuged, suspended in
1 ml protection buffer and sonicated. The protection buffer
contains 10 mM HEPES (pH 7.5) containing 100 mM
KCl, 1 mM EDTA, 1 mM EGTA, 50 Ag/ml each of
leupeptin and pepstatin A, 1 mM phenylmethylsulfonyl
fluoride, 10 mM NaF, 0.2 mM Na3VO4, 4 mM dithio-
threitol, and 1 mM diisopropylfluorophosphate and is
necessary to protect cPLA2 from the proteases present in
the granules of PMN. For experiments using fMLP as a
stimulus, 100 nM fMLP was used, and cells were stimu-
lated for 1 min. The sonicate was centrifuged for 10 min at
16,000 g to remove granules, nuclei and cellular debris,
and the supernatant was further centrifuged for 1 h at
100,000 g. In these procedures, the cPLA2 is recovered
in the cytosol since EDTA and EGTA chelate Ca2 + and
release cPLA2 that is membrane bound. The 100,000 g
supernatant was isolated and stored at 4 jC after adding
200 mg glycerol/1 ml until cPLA2 activity was assayed.
cPLA2 activity of the samples remained unchanged after 1
week of storage; however, samples were typically assayed
the following day. Soluble cPLA2 activity was determined
as previously described using 1-stearoyl-2-[14C]arachido-
noyl-GPC as the substrate and measuring [14C]AA release
[20]. Lipids were extracted by adding 4 volumes of
CHCl3/MeOH/acetic acid (2:1:0.01, v/v) + 0.05% butylated
hydroxytoluene. Labeled AA was separated from phospha-
tidylcholine by TLC using a solvent system consisting of
hexane/ethyl ether/formic acid (30:20:1, v/v); products and
standards were visualized for scraping and counting by
exposing the developed TLC plate to iodine vapors.
Specific activities were based on protein concentration,
as determined by the method of Bradford [16], using BSA
as a standard.
Experiments to evaluate the effect of the kinase inhibitors
on the phosphorylation state of cPLA2 in stimulated PMN
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were performed by Western blot analysis. Cells were treated
the same way as those that were used for cPLA2 activity
measurement except that supernatant from the 30 min,
16,000 g spin was used rather than cytosol. We must
emphasize that although the PMN sonicate contains a
variety of protease and phosphatase inhibitors, it is impor-
tant to centrifuge the PMN sonicate for at least 30 min to
remove granular material to minimize degradation of the
cPLA2. Phosphorylation of cPLA2 was determined by the
appearance of a slower migrating band (gel shift) that was
immunoreactive to the cPLA2 antibody.
2.7. PAF formation assay
Stimulus-induced PAF accumulation was quantitated
using two different methods. PAF production induced by
fMLP stimulation was measured using a modification of the
procedure described by Chilton et al. [19]. PMN were
labeled as described above, and cells (3.5 107 cells/1
ml) were incubated with or without 50 AM PD 98059
and/or 20 AM SB 203580 (30 min, 37 jC), as detailed in
the figure legends; DMSO was the inhibitor vehicle control.
PMN were then treated with or without 10 AM fMLP for 10
min. The incubations were terminated by adding 3 ml
chloroform/methanol (1:2, v/v) to the cell suspensions.
Lipids were extracted, and [3H]PAF was isolated by thin-
layer chromatography (TLC) as described below.
A23187-stimulated PAF formation was quantitated as
described [15]. Briefly, PMN were preincubated with and
without kinase inhibitors, as described above, and treated
with or without 10 AM A23187 for 10 min at 37 jC. Fifteen
seconds after stimulation, 10 ACi [3H]acetate was added to
each reaction tube. Reactions were stopped by adding 3 ml
chloroform/methanol (1:2, v/v) to the cell suspensions;
lipids were extracted and products measured as described
below.
2.8. Extraction and chromatography of lipids
Lipids were extracted from reaction mixtures using a
modification of the Bligh and Dyer [17] method; the
aqueous phase was acidified with acetic acid to lower the
pH to V 4. Authentic PC and PAF standards (50 Ag of each)
were added during extraction as carrier lipids to aid in
recovery and chromatographic separation. The organic
phases were evaporated under a stream of nitrogen and
lipids dissolved in 100 Al chloroform/methanol (4:1, v/v).
Lipids were separated using Silica gel G TLC plates
developed in chloroform/methanol/acetic acid/water
(50:25:8:4, v/v). Separated products and phospholipid
standards were visualized by exposing the developed TLC
plate to iodine vapors. In A23187-stimulated samples,
radiolabeled lipids were detected using a radiochromato-
gram imaging system (Bio-Scan Inc., Washington, DC).
Regions of the silica corresponding to labeled, individual
lipid classes were scraped, and the radioactivity was quan-
titated by liquid scintillation counting (Minaxi Tri-Carb
4000 series). Since lower amounts of [3H]PAF were formed
upon fMLP stimulation, 5 mm zonal scraping was used to
assure identification of products.
2.9. Statistical analysis
Data from experimental sets were averaged and reported
as the meanF S.E. Data were subjected to a paired, two-
tailed Student’s t-test to determine significance. Data com-
parisons that generated P values V 0.05 were considered
significantly different.
3. Results
3.1. Activation of MAP kinases and acetyltransferase
ERK-1, ERK-2, p38 MAP kinase and acetyltransferase
are activated in PMN stimulated by fMLP [11,21,22]. To
determine if stimulation by A23187 has similar effects, we
first examined ERKs and p38 MAP kinase by Western blot
analysis using whole cell sonicates obtained from control
and A23187-stimulated PMN. Both ERKs and p38 MAP
kinase underwent apparent gel shifts after treatment with
A23187 (data not shown), suggesting that the MAP kinases
had been phosphorylated. To confirm this, Western blots
using tyrosine phosphospecific antibodies against phos-
phorylated ERKs and p38 MAP kinase were performed
(Fig. 1). Panel A presents a blot of control and stimulated
PMN sonicates using antibodies that selectively recognize
ERKs phosphorylated on the tyrosine of their regulatory
TEY sequence. Stimulation with A23187 induced phos-
phorylation of ERK-1 (p44), ERK-2 (p42) and p40, an
ERK-like species that is likely a breakdown product of
Fig. 1. Activation of MAP kinases by A23187. PMN (3.0 107 cells/3 ml)
were stimulated with 10 AMA23187 for 10 min. Cells were sonicated in the
presence of a protease and phosphatase protection buffer, and samples
(2.5 105 cell equivalents) were analyzed by Western blot analysis as
described in Experimental procedures. (A) Western blot of control and
stimulated PMN sonicate using ERK antibodies that recognize ERKs
phosphorylated at their regulatory TEY sequence. (B) Western blot analysis
of control and stimulated PMN using antibodies that recognize p38 MAP
kinase phosphorylated at its regulatory TGY sequence. Blots shown are
representative samples from three independent experiments.
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p44 (J.S. Owen and R.L. Wykle, unpublished observations).
Phosphorylated p38 MAP kinase was also observed using
an antibody that recognizes its tyrosine-phosphorylated
regulatory TGY sequence (panel B). In a final set of
experiments, we examined the impact of Ca2 + ionophore
on acetyltransferase activity. A23187 (10 AM; 10 min)
increased PMN acetyltransferase activity four-fold (Fig.
2). These results indicate that stimulation of PMN with
either A23187 or fMLP [11,21,22] leads to the activation of
ERK-1, ERK-2, p38 MAP kinase and acetyltransferase.
3.2. Effects of ERK and p38 MAP kinase inhibitors on
acetyltransferase activity
We [5] and others [4,23,24] have shown that treatment of
PMN with 50 AM PD 98059 or 20 AM SB 203580 for 30
min selectively inhibits f 80% of their respective ERK or
p38 MAP kinase responses to test stimuli [21]. PMN treated
at these concentrations of inhibitors, alone or in combina-
tion, for 30 min and then challenged for up to 20 min
showed no change in their exclusion of Trypan blue (data
not shown), did not leak cytosolic lactic acid dehydrogenase
[5], and therefore remained intact. While SB 203580 has
been shown to have nonspecific inhibitory effects on several
enzymes [25], 50 AM PD 98059 has no inhibitory effect on
p38 MAP kinase, and conversely, 20 AM SB 203580 has no
effect on ERK activity [21].
We measured acetyltransferase activity in A23187-
stimulated PMN that had been treated for 30 min with
SB 203580 and/or PD 98059 to assess the relative contri-
bution of the kinase pathways to the enzyme’s activation. A
basal level of acetyltransferase activity was detected in un-
stimulated PMN (22.8F 0.01 nmol PAF/mg/min), which
was unaffected by preincubation with SB 203580 and/or
PD 98059 (Fig. 2). However, SB 203580 completely in-
hibited the stimulatory effect of A23187 on acetyltrans-
ferase activity (P < 0.05). In contrast, PD 98059 had no
significant effect under the same conditions. A combination
of both inhibitors reduced stimulated acetyltransferase
activity to the same level as that measured with the p38
MAP kinase inhibitor alone. Hence, p38 MAP kinase but
not ERK-1 or ERK-2, appears critical for the activation of
acetyltransferase induced by either a receptor agonist [11]
or Ca2 + ionophore.
3.3. Effects of various stimuli on CoA-IT activity in PMN
CoA-IT has been shown to form lyso-PAF from 1-O-
alkyl-2-arachidonoyl-GPC in the presence of lyso-PE, sug-
gesting, along with other data [26], that it plays a role in
PAF synthesis [27]. Two reports indicate that CoA-IT
activity in cells rises modestly in response to stimulation
of PMN with TNFa [28] or macrophages with LPS [29] and
therefore may play a regulatory role in PAF synthesis. To
test this in our system, CoA-IT activity was measured in
microsomal membrane preparations obtained from PMN
treated with a variety of stimuli (Fig. 3). Stimulation of
PMN with TNFa, fMLP or PMA did not affect CoA-IT
activity as measured in an in vitro system. (Typically,
approximately 5–10% of the labeled substrate was con-
verted to product.) In contrast, stimulation with A23187
reduced CoA-IT activity by 40% (P < 0.05). This last result
was studied earlier in A23187-stimulated PMN and found to
be due to the build-up of endogenous competing substrates
(see Discussion). Moreover, pretreatment of PMN with
Fig. 3. Effect of various stimuli on CoA-IT activity. PMN (3.5 107 cells/1
ml) were stimulated with either TNFa (3.16 nM; 10 min), A23187 (10 AM;
10 min), fMLP (10 AM; 10 min) or PMA (100 nM; 5 min). Microsomal
fractions were prepared, and CoA-IT activity was measured with an
acceptor assay as described in Experimental procedures. Results are given
as the meansF S.E. The control level of CoA-IT activity was 7.05F 0.46
pmol/mg/min. For each stimulus, the number of experiments performed is
as follows: TNFa (n= 22), A23187 (n= 7), PMA (n= 3) and fMLP (n= 3).
The P value from a two-tailed, paired, Student’s t-test is as follows: P < 0.05
for unstimulated PMN versus A23187-stimulated PMN (*).
Fig. 2. Effect of kinase inhibitors on acetyltransferase activity. PMN
(3.5 107 cells/1 ml) were incubated for 30 min with 20 AM SB 203580,
50 AM PD 98059, both drugs, or DMSO vehicle. Cells were then stimulated
with 10 AM A23187 for 10 min. Microsomal fractions were prepared, and
acetyltransferase activity was assayed as described in Experimental
procedures. Results shown are the meansF S.E. of three experiments.
Statistically significant differences (paired, two-tailed, Student’s t test) are
indicated.
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either or both kinase inhibitors had no effect on measured
CoA-IT activity in control or treated PMN (data not shown).
Finally, we were unable to activate CoA-IT in microsomal
preparations in vitro using recombinant, active p38, ERK-1
and/or ERK-2 in the presence or absence of PMN soluble
fraction (data not shown). Under similar cell-free condi-
tions, p38 MAP kinase activated microsomal acetyltransfer-
ase [11] as well as recombinant cPLA2, while ERK-1 and
ERK-2 activated only recombinant cPLA2 (J.S. Owen and
R.L. Wykle, unpublished observations). We conclude that
CoA-IT is not regulated by ERK1/2 or p38 MAP kinase and
shows no stimulation of activity in PMN challenged with
diverse stimuli.
3.4. Effects of ERK and p38 MAP kinase inhibitors on
stimulated cPLA2 activity
To measure the effects of the MAP kinase inhibitors on
cPLA2 activation, cells were stimulated in the presence or
absence of SB 203580 and/or PD 98059, and the recovered
cytosol was assayed for cPLA2 activity (Fig. 4). Since
calcium promotes cPLA2 binding to membranes, EDTA
and EGTA are included in the cell disruption mixture to
remove free calcium and maximize recovery of the enzyme
in the cytosolic fraction [20]. DTT is included in both the
assay buffer and cell disruption mixture to destroy cPLA2
activity. Using this procedure, >95% of the total cPLA2
Fig. 4. Effects of the MAP kinase inhibitors on fMLP- and A23187-stimulated cPLA2 activity. PMN (3 107/3 ml) were treated with either (A) fMLP (100
nM; 1 min), (B) A23187 (10 AM; 2 min) or vehicle at 37 jC. Cytosolic fractions were prepared and assayed for cPLA2 activity as described in Experimental
procedures. Data represent the meansF S.E. of three (fMLP) or five (A23187) separate experiments. P values from a two-tailed, paired, Student’s t-test are as
follows. (A) P< 0.05 for fMLP-stimulated PMN versus control (*) and versus fMLP-stimulated PMN treated with SB 203580 (x), PD98059 (E), or both
inhibitors ( ); there is not a significant difference between control PMN and fMLP-treated PMN with both inhibitors; (B) P< 0.05 for A23187-stimulated PMN
versus control (*) and versus A23187-stimulated PMN treated with SB 203580 (x), PD98059 (E), or both inhibitors ( ) P< 0.05 for * versus . Inset: PMN
(3 107/3 ml) were treated with 10 AM A23187 for the indicated time periods. Cytosolic fractions were prepared and cPLA2 activity was measured as
described. Maximal cPLA2 activity occurred at 2 min. Consequently, the effects of A23187 on cPLA2 activity and its phosphorylation state (Fig. 5) were
measured after 2 min stimulation.
Fig. 5. Inhibition of cPLA2 phosphorylation by SB 203580 and/or PD 98059. PMN were isolated and stimulated in the presence or absence of the MAP kinase
inhibitors and then analyzed by Western blotting as described in Experimental procedures. Phosphorylation of cPLA2 was determined by the appearance of a
higher molecular weight band (gel shift) in the immunoblots. The blot shown is representative of six independent experiments.
P.R.S. Baker et al. / Biochimica et Biophysica Acta 1592 (2002) 175–184180
activity is recovered in the cytosol [20]. Treatment of PMN
with 100 nM fMLP increased cPLA2 activity 65% relative
to control (Fig. 4A; P < 0.05). Use of either PD 98059 or SB
203580 alone partially inhibited (40–60%) this response
(P < 0.05), whereas a combination of both drugs totally
ablated fMLP-induced cPLA2 activation (P < 0.05 for
fMLP-stimulated PMN versus fMLP-stimulated PMN trea-
ted with either or both inhibitors). This pattern of inhibition
is clearly seen in cPLA2 Western blots (Fig. 5). cPLA2
underwent an apparent gel shift in fMLP-treated PMN,
which was partially reduced when the PMN were pretreated
with either of the MAP kinase inhibitors alone. When both
inhibitors were used, the fMLP-induced cPLA2 gel shift was
completely blocked. Stimulation of PMN with 10 AM
A23187 likewise resulted in a rise in cPLA2 activity. The
effect peaked at 2 min and returned to control levels within
5 min (Fig. 4B; inset). Accordingly, we evaluated cPLA2
activity at 2 min after stimulation. The stimulation with
A23187 resulted in a modest but statistically significant
30% increase in cPLA2 activity (P < 0.05). Preincubation
with SB 203580 or PD 98059 decreased to near control
values the A23187-stimulated activation of cPLA2, whereas
the combination of both inhibitors resulted in a further
decrease in cPLA2 activity to below that observed in resting
cells (P < 0.05; Fig. 4B). Relative to the latter finding, we
stress that cell viability under these experimental conditions
was z 97%, as measured by Trypan blue exclusion and
furthermore that the inhibitors have no direct effect on
cPLA2 activity in enzymatic assays at the concentrations
used here (data not shown). In some experiments, cPLA2
Western blot analysis of PMN treated with A23187 showed
a decrease in immunoreactive cPLA2 to below control levels
(data not shown). This observation suggests that A23187
may induce degradation of cPLA2, which may, in part,
explain the decrease in cPLA2 activity to below control
levels. However, despite some loss of the enzyme, the
Western blots do show that the phosphorylation state of
cPLA2 correlates with the activity data (Fig. 5). Either
inhibitor alone partially attenuates the gel shift, and both
inhibitors combined completely block cPLA2 phosphoryla-
tion. These results suggest that as with fMLP, A23187-
stimulated cPLA2 activity is regulated by both ERKs and
p38 MAP kinase.
3.5. Effects of ERK and p38 MAP kinase inhibitors on
A23187- and fMLP-stimulated PAF formation
Unstimulated PMN synthesize little PAF (f 110 dpm
[3H]acetate incorporated into PAF), and incubation with SB
203580, PD 98059 or both drugs did not significantly alter
the basal PAF formation. Stimulation of PMN with A23187
resulted in a 68-fold increase in PAF formation (f 7000
dpm; P < 0.05); this dramatic increase was reduced 60% by
SB 203580, 35% by PD 98059, and 85% using a combina-
tion of the drugs (Fig. 6). Cells stimulated with 10 AM
fMLP exhibited a smaller but significant, 42F 11% increase
in PAF formation relative to unstimulated cells (800–1500
dpm of labeled PC converted to PAF; P < 0.05), which SB
203580 inhibited 60%. Although the ERK pathway inhibitor
had no significant effect on fMLP-stimulated PAF produc-
Fig. 6. Effect of kinase inhibitors on A23187-stimulated PAF formation.
PMN (3.5 107 cells/1 ml) were incubated for 30 min with 20 AM SB
203580, 50 AM PD 98059, both drugs, or DMSO vehicle in PBS containing
1.4 mM Ca2 +. PMN were then stimulated for 10 min by adding 10 AM
A23187 along with 10 ACi [3H]acetate. PAF was extracted and quantitated
as described in Experimental procedures. Results shown are the means
F S.E. of three experiments. Typically, 7000 dpm [3H]acetate was
incorporated into PAF in A23187-treated PMN. P values from a two-tailed,
paired, Student’s t-test are as follows: P< 0.05 for A23187-stimulated PMN
versus control (*) and versus A23187-stimulated PMN treated with SB
203580 (x), PD98059 (E), or both inhibitors ( ); P< 0.05 for x versus .
Fig. 7. Effect of kinase inhibitors on fMLP-stimulated PAF formation. PMN
(3.5 107 cells/1 ml) were prelabeled with [3H]lyso-PAF (60,000 dpm/
tube) in PBS without Ca2 + for 60 min at 37 jC. PMN were then incubated
for 30 min with 20 AM SB 203580, 50 AM PD 98059, both drugs, or
DMSO vehicle in PBS containing 1.4 mM Ca2 +. PMN were subsequently
stimulated for 10 min with 10 AM fMLP or with vehicle only as control;
PAF was extracted and quantitated as described in Experimental
procedures. Results shown are the meansF S.E. of eight independent
experiments. Approximately 800–1500 dpm of labeled PC was converted
to [3H]PAF. P values from a two-tailed, paired, Student’s t-test are as
follows: P< 0.05 for fMLP-stimulated PMN versus control (*) versus
fMLP-stimulated PMN treated with SB 203580 (x) or both inhibitors ( );
P < 0.05 for x versus .
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tion, its combination with SB 203580 completely ablated
stimulated PAF synthesis in PMN (Fig. 7). Overall, our
studies indicate that the ERKs and p38 MAP kinase con-
tribute to PAF formation induced by both stimulus types. In
the absence of ERK activation, p38 MAP kinase appears to
provide sufficient activation of cPLA2 and acetyltransferase
to support low levels of PAF formation.
4. Discussion
PAF synthesis has been implicated in a number of
pathological conditions such as necrotizing entercolitis
[30], ischemic reperfusion injury [31], multiple organ failure
[32] and anaphylaxis [33]. Consequently, defining the
regulation of stimulus-induced PAF formation could con-
tribute to effective therapeutic strategies to control these and
other inflammatory diseases. In many cells, including PMN,
PAF synthesis proceeds through a remodeling pathway that
appears to involve cPLA2 [34], acetyltransferase [35,36] and
CoA-IT [18,26]. Our present studies using the receptor
agonist fMLP and the Ca2 + ionophore A23187 indicate
that MAP kinase regulation of cPLA2 and acetyltransferase,
but not CoA-IT, govern stimulus-induced PAF synthesis.
Fig. 2 shows that SB 203580, a known inhibitor of p38
MAP kinase, blocks A23187-stimulated acetyltransferase
activity, whereas PD 98059, a known inhibitor of the ERK
pathway, has little effect. Combined with our findings in
fMLP-stimulated PMN [11], these data indicate that p38
MAP kinase bears major, if not sole, responsibility for
activating the acetyltransferase in PMN. As seen in Fig. 2,
however, resting PMN exhibit appreciable acetyltransferase
activity. Although this baseline activity can be somewhat
further reduced to lower levels by alkaline phosphatase
treatment of the microsomal membrane fractions (suggesting
that the acetyltransferase may be partially activated during
the PMN isolation process), there remains a significant
acetyltransferase activity [11]. We speculate that the basal
level activity is sufficient to allow PAF synthesis to proceed
at a reduced rate, provided that lyso-PAF is available.
In addition to being released directly from its precursor by
PLA2, lyso-PAF can be formed by PLA2 hydrolysis of
plasmenylethanolamine and transacylation via CoA-IT
[37]. Winkler et al. [28] reported a modest increase in
CoA-IT activity in PMN stimulated with TNFa, and Svetlov
et al. [29] reported an increase in CoA-IT activity, as
measured by a donor assay but not by an acceptor assay, in
a murine macrophage cell line, IC-21, challenged by LPS.
We found no change in CoA-IT activity in PMN challenged
with fMLP, TNFa or PMA (Fig. 3) as measured by either an
acceptor or a donor assay. We are unable to explain why our
findings differ from those of the earlier cited reports. The
apparent decrease in CoA-IT activity in PMN treated with
A23187 (Fig. 3) is explained by Venable et al. [27]. In these
studies, we found that the apparent decrease in CoA-IT
activity in Ca2 + ionophore-challenged PMN could be attrib-
uted to substrate competition by unlabeled lyso-phospholi-
pid, i.e., 1-O-alk-1V-enyl-2-lyso-GPE, rather than to
inhibition of the enzymatic activity per se. We found that
washing microsomal membrane preparations from A23187-
stimulated PMN with albumin, thereby removing competing
unlabeled lyso-phospholipid, effectively restored CoA-IT
activity to control levels [27]. Furthermore, addition of
lyso-plasmenylethanolamine (at concentrations found in
stimulated preparations) mimicked the apparent decrease in
activity observed in the stimulated membrane preparations.
Attempts to increase CoA-IT activity in PMN microsomal
membranes using recombinant, active p38 MAP kinase,
ERK-1 or ERK-2 in the presence or absence of PMN soluble
fraction were unsuccessful (data not shown). Furthermore,
preincubation of PMN with the MAP kinase inhibitors prior
to stimulation with either TNFa or A23187 had no affect on
CoA-IT activity, as determined in our in vitro assay (data not
shown). We therefore conclude that under the conditions of
our studies, CoA-IT is best viewed as a constitutively active
enzyme whose contribution to lyso-PAF formation is pas-
sive, i.e., dependent upon the availability of PLA2-generated
1-O-alk-1V-enyl-2-lyso-GPE.
In contrast to acetyltransferase and CoA-IT, cPLA2
activation in response to treatment with fMLP appears to
involve both ERK and p38 MAP kinases. Individually, PD
98059 and SB 203580 partially inhibited cPLA2 activation,
while a combination of both drugs completely inhibited its
activation (Fig. 4A). These results differ from the findings
by Syrbu et al. [38] that neither PD 98059 nor SB 203580
inhibited fMLP-induced phosphorylation of cPLA2 (a com-
bination of the two drugs was not tested). However, the
cPLA2 Western blot data reported here (Fig. 5) indicate that
Fig. 8. Proposed regulation of stimulated PAF formation via the remodeling
pathway in PMN. cPLA2 can be phosphorylated by both ERKs and p38
MAP kinase. Once active, cPLA2 hydrolyzes arachidonate from 1-O-alkyl-
2-arachidonoyl-GPC, which can be converted to inflammatory eicosanoids,
and the resultant lyso-PAF is subject to acetylation by acetyl-CoA:1-O-
alkyl-2-lyso-sn-GPC acetyltransferase. CoA-IT also generates lyso-PAF if
an appropriate acceptor lysophospholipid is present; however, the enzyme
is not regulated by signaling. The constitutive activity of acetyltransferase
can convert lyso-PAF that is generated by either pathway to PAF, but when
acetyltransferase is activated by p38 MAP kinase, increased PAF formation
is observed. Because PAF is such a powerful agonist, the lower amounts of
PAF formed in the absence of acetyltransferase activation may be sufficient
to induce biological effects.
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individually, the two inhibitors do indeed partially block the
cPLA2 gel shift in fMLP- and A23187-stimulated PMN.
Our results are consistent with those of Borsch-Haubold et
al. [39] who reported that SB 203580 inhibited phosphor-
ylation of cPLA2. Moreover, our treatment of PMN with SB
203580 or PD 98059 reduced A23187-stimulated cPLA2
activity to near unstimulated levels (Fig. 4, panel B). A
combination of the drugs reduced cPLA2 activity byf 50%
in A23187-challenged (Fig. 4B) but not fMLP-challenged
or resting PMN (Fig. 4A). Gel shift analysis (Fig. 5) to
measure the phosphorylation state of cPLA2 in A23187-
stimulated PMN correlates with the activity data. However,
some of the immunoblots also indicate that in A23187-
stimulated PMN, the amount of cPLA2 decreases as com-
pared to control cells. This last observation may be ex-
plained by recent studies that show cPLA2 can be degraded
by caspase-3 in A23187- and TNFa-stimulated cells [40,41].
The results presented here indicate that both ERKs and
p38 MAP kinases participate in the activation of cPLA2.
Although phosphorylation of the enzyme by p38 MAP
kinase has been controversial [7,42–44], it is becoming
increasingly clear that the kinase does modulate cPLA2
activity. As shown in Figs. 4 and 5, the activation of cPLA2,
at least as it occurs in PMN treated with fMLP or A23187, is
partially blocked by the addition of a p38 MAP kinase
inhibitor. This result is compatible with studies by Kramer et
al. [43,45], who demonstrated the incorporation of radio-
labeled phosphate into recombinant cPLA2 by a p38 MAP
kinase-enriched column fraction from stimulated platelets.
Recently, Borsch-Haubold et al. [46] reported direct phos-
phorylation of cPLA2 by three human isoforms of p38 MAP
kinase: p38a, h and y. Experiments in our laboratory
confirm this result (J.S. Owen and R.L. Wykle; unpublished
observations). Since kinases downstream of p38 MAP
kinase may also phosphorylate and activate cPLA2 [47],
we interpret our results as indicating that cPLA2 activity is
directly modulated by ERKs and either directly or indirectly
by p38 MAP kinases.
Evaluation of the individual enzymes of the remodeling
pathway suggests that both p38 MAP kinase and ERK
cascades are intimately involved in stimulated PAF syn-
thesis. However, the relative contribution of the two MAP
kinase pathways to PAF formation cannot be determined in
the cell-free systems used. Consequently, modulation of
PAF formation was evaluated in intact PMN stimulated
with A23187 or fMLP (Figs. 6 and 7). We found that in
either A23187- or fMLP-stimulated PMN, blocking the p38
MAP kinase pathway significantly attenuates PAF synthe-
sis. However, in order to optimally block stimulated PAF
formation, the ERK pathway must also be inhibited. These
results suggest a partial redundancy of MAP kinase signal-
ing with respect to PAF synthesis. Furthermore, since both
stimuli similarly activate the two MAP kinase pathways and
give similar inhibition profiles, our results indicate that
A23187 is indeed a suitable model stimulus for studies of
PAF biosynthesis.
In summary, our results support a model in which both
ERK and p38 MAP kinase cascades control flux through the
remodeling pathway by activating two rate-limiting
enzymes, cPLA2 and acetyltransferase (Fig. 8). Although a
role for CoA-IT in PAF synthesis is recognized, it appears
that this enzyme is controlled not by the MAP kinases but
by the availability of its lysophospholipid substrate, which
is provided by a PLA2. Furthermore, these results suggest
that therapeutic strategies to control PAF-induced inflam-
mation by inhibiting the regulatory mechanism of PAF
formation would seem better aimed at blocking both the
ERK and p38 MAP kinase pathways.
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